(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.56%) $78.92
(-0.87%) $2.18
(0.14%) $2 334.40
(0.29%) $27.70
(0.17%) $966.50
(0.02%) $0.928
(0.03%) $10.83
(0.03%) $0.796
(-0.02%) $91.32
Quarter results today
(bmo 2024-05-07)
Expected move: +/- 7.08%
2.95% $ 25.16
@ $31.40
Emitido: 11 mar 2024 @ 10:33
Retorno: -19.87%
Señal anterior: mar 8 - 13:41
Señal anterior:
Retorno: -7.29 %
Live Chart Being Loaded With Signals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma...
Stats | |
---|---|
Volumen de hoy | 619 229 |
Volumen promedio | 1.29M |
Capitalización de mercado | 3.12B |
EPS | $-1.030 ( 2024-02-06 ) |
Próxima fecha de ganancias | ( $-0.0600 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.08 |
ATR14 | $0.0230 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-02 | Vakiener Victoria | Sell | 1 799 | Common Stock |
2024-04-01 | Hamilton James C | Sell | 6 000 | Common Stock |
2024-03-20 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-19 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-18 | Lu Hongbo | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
13.81 |
Last 100 transactions |
Buy: 903 379 | Sell: 696 131 |
Volumen Correlación
Arrowhead Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
PRDS | 0.893 |
RDUS | 0.892 |
EYPT | 0.874 |
JAKK | 0.869 |
SSYS | 0.868 |
RLAY | 0.864 |
PLRX | 0.864 |
MDXH | 0.863 |
ATLC | 0.86 |
MCRB | 0.859 |
10 Correlaciones Más Negativas | |
---|---|
GMII | -0.885 |
RMRM | -0.871 |
MTSI | -0.87 |
COMT | -0.869 |
MEUSW | -0.861 |
DHC | -0.86 |
ALGM | -0.86 |
SBBP | -0.85 |
VTRU | -0.849 |
BGCP | -0.849 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arrowhead Pharmaceuticals Correlación - Moneda/Commodity
Arrowhead Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $240.74M |
Beneficio Bruto: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2023 |
Ingresos: | $240.74M |
Beneficio Bruto: | $228.24M (94.81 %) |
EPS: | $-1.920 |
FY | 2022 |
Ingresos: | $243.23M |
Beneficio Bruto: | $232.81M (95.72 %) |
EPS: | $-1.670 |
FY | 2021 |
Ingresos: | $138.29M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.360 |
Financial Reports:
No articles found.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico